Order: ceftriaxone 2 g in 100 mL of 0.9% NaCI (normal saline solution) over 30 minutes

Available: Macro drip set: 15 gtt/mL

Calculate the IV flow rate in gtt/min.

A) Distribution:. Distribution refers to the process by which a drug is transported throughout the body after it is absorbed into the bloodstream. It involves the movement of the drug to various tissues and organs, where it can exert its effects. Factors such as blood flow, tissue permeability, and protein binding affect distribution.

B) Metabolism:
Metabolism refers to the biochemical process by which the body breaks down drugs into metabolites, usually in the liver. Metabolism can transform drugs into more easily excreted forms and sometimes alters the drug’s activity. It is essential for drug clearance and can affect drug efficacy and toxicity.

C) Absorption:
Absorption is the first step in pharmacokinetics, where the drug enters the bloodstream after being administered. It occurs primarily in the gastrointestinal (GI) tract for oral medications but can also happen in other routes like subcutaneous or intramuscular injections. The rate and extent of absorption are influenced by factors such as drug formulation, route of administration, and presence of food.

D) Synthesis:
Synthesis refers to the process of creating substances, such as drugs or other compounds, typically within the body or in a laboratory setting. While drug synthesis is crucial in drug development, it is not a step involved in the movement or processing of drugs within the body (which is what pharmacokinetics describes). Pharmacokinetics focuses on how the body handles drugs, not how they are created.

A) Patients with hypertension
Low molecular weight heparin (LMWH) is not primarily used to treat hypertension. Hypertension (high blood pressure) is typically managed with antihypertensive medications like ACE inhibitors, beta-blockers, diuretics, or calcium channel blockers. LMWH is an anticoagulant, which works to prevent blood clots rather than controlling blood pressure.

B) Patients with asthma
LMWH is not typically used to treat asthma. Asthma is a chronic respiratory condition that is usually managed with bronchodilators (e.g., albuterol) and anti-inflammatory drugs such as corticosteroids. While patients with asthma may be at risk for blood clots under certain conditions (e.g., severe asthma exacerbations, immobility), LMWH is not a first-line treatment for asthma.

C) Patients with diabetes
While people with diabetes may be at an increased risk of developing blood clots, LMWH is not specifically used to treat diabetes. Diabetes is typically managed with insulin, oral hypoglycemic agents, lifestyle modifications, and other medications to control blood glucose levels. LMWH is an anticoagulant used for conditions that require prevention of clot formation, such as deep vein thrombosis (DVT).

D) Patients with deep vein thrombosis (DVT)
LMWH is commonly prescribed to patients with deep vein thrombosis (DVT). DVT occurs when a blood clot forms in a deep vein, usually in the legs. LMWH is a type of anticoagulant that prevents the formation of further clots by inhibiting factors involved in blood clotting. It is especially effective for patients with DVT or those at high risk for thromboembolic events, such as after surgery or during prolonged immobility. LMWH provides more predictable anticoagulation and requires less frequent monitoring than unfractionated heparin, making it ideal for outpatient management and in hospital settings.